Suppr超能文献

乳腺浸润性大汗腺癌的预后是否比浸润性导管癌更差:来自监测、流行病学和最终结果(SEER)数据库的证据。

Dose invasive apocrine adenocarcinoma has worse prognosis than invasive ductal carcinoma of breast: evidence from SEER database.

作者信息

Zhang Ning, Zhang Hanwen, Chen Tong, Yang Qifeng

机构信息

Department of Breast Surgery, Qilu Hospital, Shandong University, Jinan, 250012, Shandong Province, People's Republic of China.

Pathology Tissue Bank, Qilu Hospital, Shandong University, Jinan, 250012, Shandong Province, People's Republic of China.

出版信息

Oncotarget. 2017 Apr 11;8(15):24579-24592. doi: 10.18632/oncotarget.15597.

Abstract

BACKGROUND

Invasive apocrine adenocarcinoma (AAC) of breast is a rare histopathological subtype of breast carcinomas. We aim to investigate the different characteristics and prognostic outcomes between AAC and invasive ductal carcinoma (IDC) of breast cancer.

RESULTS

AAC patients presented with older ages, more aggressive behaviors, lower ER and PR proportions, higher HER2 amplification rates and less application of breast-conserving therapy and adjuvant chemotherapy compared to IDC patients. Long-term OS and DSS were both worse in ACC patients (p = 0.006, p = 0.012 respectively) than in IDC patients by Kaplan-Meier analysis. However, no significant difference was detected in DSS (p = 0.181) and OS (p = 0.116) between the matched two histological subtypes. Further subgroup analysis indicated that AJCC stage, ER status, PR status and HER2 status may be principal confounders for AAC prognosis.

MATERIALS AND METHODS

With accession to the Surveillance, Epidemiology and End Result (SEER) database, a total of 260,596 patients met the eligibility criteria. Clinicopathological characteristics were compared between groups using Chi-square test. Univariate and multivariate analyses were applied to evaluate the overall survival (OS) and disease-specific survival (DSS). Subgroup analyses summarized the hazard ratio (HR) of AAC versus IDC using a forest plot.

CONCLUSIONS

AAC had unique clinicopathological characteristics and it tended to be a more aggressive type than IDC. However, the worse prognosis was diminished after matching for demographic and clinicopathological factors. Deeper insights into AAC are in need to contribute to individualized and tailored therapy, which thereby may improve clinical management and outcomes.

摘要

背景

乳腺浸润性大汗腺癌(AAC)是乳腺癌一种罕见的组织病理学亚型。我们旨在研究AAC与乳腺浸润性导管癌(IDC)之间不同的特征和预后结果。

结果

与IDC患者相比,AAC患者年龄更大,行为更具侵袭性,雌激素受体(ER)和孕激素受体(PR)比例更低,人表皮生长因子受体2(HER2)扩增率更高,保乳治疗和辅助化疗的应用更少。通过Kaplan-Meier分析,AAC患者的长期总生存期(OS)和疾病特异性生存期(DSS)均比IDC患者差(分别为p = 0.006,p = 0.012)。然而,在匹配的两种组织学亚型之间,未检测到DSS(p = 0.181)和OS(p = 0.116)的显著差异。进一步的亚组分析表明,美国癌症联合委员会(AJCC)分期、ER状态、PR状态和HER2状态可能是AAC预后的主要混杂因素。

材料与方法

通过访问监测、流行病学和最终结果(SEER)数据库,共有260596例患者符合纳入标准。使用卡方检验比较组间的临床病理特征。应用单因素和多因素分析来评估总生存期(OS)和疾病特异性生存期(DSS)。亚组分析使用森林图总结了AAC与IDC的风险比(HR)。

结论

AAC具有独特的临床病理特征,且往往比IDC更具侵袭性。然而,在匹配人口统计学和临床病理因素后,较差的预后有所减轻。需要对AAC有更深入的了解,以促进个体化和针对性治疗,从而改善临床管理和治疗结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78f4/5421871/92cc8c9d4774/oncotarget-08-24579-g001.jpg

相似文献

3
Comparative prognostic analysis for triple-negative breast cancer with metaplastic and invasive ductal carcinoma.
J Clin Pathol. 2019 Jun;72(6):418-424. doi: 10.1136/jclinpath-2018-205544. Epub 2019 Mar 14.
9
A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma.
Breast Cancer Res Treat. 2008 Oct;111(3):541-7. doi: 10.1007/s10549-007-9809-z. Epub 2007 Nov 18.

引用本文的文献

1
Apocrine Breast Carcinoma With an Atypical Immunohistochemical Profile: A Case Report.
Cureus. 2025 Aug 1;17(8):e89193. doi: 10.7759/cureus.89193. eCollection 2025 Aug.
2
Apocrine Breast Cancer: A Case Report.
Cureus. 2024 Apr 7;16(4):e57789. doi: 10.7759/cureus.57789. eCollection 2024 Apr.
3
Androgen receptor function and targeted therapeutics across breast cancer subtypes.
Breast Cancer Res. 2022 Nov 14;24(1):79. doi: 10.1186/s13058-022-01574-4.
4
Prognostic relevance of mixed histological subtypes in invasive breast carcinoma: a retrospective analysis.
J Cancer Res Clin Oncol. 2023 Jul;149(8):4967-4978. doi: 10.1007/s00432-022-04443-x. Epub 2022 Oct 31.
6
HER2-positive apocrine carcinoma of the breast: a population-based analysis of treatment and outcome.
Breast Cancer Res Treat. 2022 Jun;193(2):523-533. doi: 10.1007/s10549-022-06578-4. Epub 2022 Mar 30.
8
Neoadjuvant targeted therapy for apocrine carcinoma of the breast: A case report.
World J Clin Cases. 2020 Dec 6;8(23):6036-6042. doi: 10.12998/wjcc.v8.i23.6036.

本文引用的文献

2
Immunohistochemical and molecular profiling of histologically defined apocrine carcinomas of the breast.
Hum Pathol. 2015 Sep;46(9):1350-9. doi: 10.1016/j.humpath.2015.05.017. Epub 2015 Jun 5.
3
Apocrine carcinoma of the breast: a comprehensive review.
Histol Histopathol. 2013 Nov;28(11):1393-409. doi: 10.14670/HH-28.1393. Epub 2013 Jun 17.
5
Triple negative breast cancer: clinical characteristics in the different histological subtypes.
Breast. 2013 Oct;22(5):761-6. doi: 10.1016/j.breast.2013.01.009. Epub 2013 Feb 15.
6
Immunohistochemically defined subtypes and outcome of apocrine breast cancer.
Clin Breast Cancer. 2013 Apr;13(2):95-102. doi: 10.1016/j.clbc.2012.11.004. Epub 2012 Dec 14.
7
The clinicopathologic features of molecular apocrine breast cancer.
Korean J Pathol. 2012 Apr;46(2):169-76. doi: 10.4132/KoreanJPathol.2012.46.2.169. Epub 2012 Apr 25.
8
Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome.
Clin Breast Cancer. 2013 Feb;13(1):31-9. doi: 10.1016/j.clbc.2012.09.002. Epub 2012 Oct 24.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验